A Phase 3 Trial Investigating Blinatumomab (IND#117467 NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma(B-LLy)
Brief description of study
The purpose of the trial is to determine the safety and efficacy of the investigational medicine, blinatumomab plus standard treatment for patients who have Standard Risk B-cell Lymphoblastic Leukemia (SR B-ALL) or B-cell Lymphoblastic Leukemia and you have Down syndrome of any risk level. There are two parts in this study. The first part is to collect information about your leukemia and your response to the first phase of treatment which is to remove all visible signs of leukemia. Part II of the study is to get rid of any remaining leukemia cells and keep the leukemia from coming back.
Clinical Study Identifier: s19-01032
ClinicalTrials.gov Identifier: NCT03914625
Principal Investigator:
Chana Glasser.
Other Investigators:
Christeen Azmy,
Lia Phillips,
Mark E Weinblatt,
Sylwia Jasinski,
Joshua Isao Chan.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
